Recently, we suggested afzelin (kaempferol 3-O-α-L-rhamnopyranoside) as the structure suppressing glycosylation (e.g., by inhibition of C1GalT1, ST6GalNAcT, ST3GalT expression) in gastric cancer cells and in this way acting as a potential anti-cancer agent [38]. Here, C1GALT1 is linked to gastric cancer.